168 related articles for article (PubMed ID: 34379840)
1. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply.
Fan R; Hou J
Aliment Pharmacol Ther; 2021 Sep; 54(5):724-725. PubMed ID: 34379840
[No Abstract] [Full Text] [Related]
2. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy.
Yip TC; Wong VW
Aliment Pharmacol Ther; 2021 Sep; 54(5):722-723. PubMed ID: 34379832
[No Abstract] [Full Text] [Related]
3. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
Pol S; Luzivika Nzinga C; Fontaine H; Carrat F;
Aliment Pharmacol Ther; 2021 Mar; 53(5):659. PubMed ID: 33566398
[No Abstract] [Full Text] [Related]
4. Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
Warner N; Locarnini S
Antivir Ther; 2009; 14(2):139-42. PubMed ID: 19430088
[No Abstract] [Full Text] [Related]
5. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply.
Lee HA; Kim SU
Aliment Pharmacol Ther; 2020 Sep; 52(5):913-914. PubMed ID: 32852833
[No Abstract] [Full Text] [Related]
6. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
7. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
9. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.
Fan R; Niu J; Ma H; Xie Q; Cheng J; Rao H; Dou X; Xie J; Zhao W; Peng J; Gao Z; Gao H; Chen X; Chen J; Li Q; Tang H; Zhang Z; Ren H; Cheng M; Liang X; Zhu C; Wei L; Jia J; Sun J; Hou J;
Aliment Pharmacol Ther; 2021 Aug; 54(3):329-338. PubMed ID: 34157146
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis B and hepatocellular carcinoma.
McClune AC; Tong MJ
Clin Liver Dis; 2010 Aug; 14(3):461-76. PubMed ID: 20638025
[TBL] [Abstract][Full Text] [Related]
11. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
12. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Lee HA; Seo YS; Kim SU
Gastroenterology; 2020 Jun; 158(8):2310-2311. PubMed ID: 32201178
[No Abstract] [Full Text] [Related]
13. Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
Kamal F; Khan MA
Gastroenterology; 2020 Jun; 158(8):2311-2312. PubMed ID: 32201182
[No Abstract] [Full Text] [Related]
14. Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Huang R; Wang J; Wu W; Yan X; Wu C
Hepatology; 2020 Jun; 71(6):2173-2174. PubMed ID: 31858599
[No Abstract] [Full Text] [Related]
15. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria.
Sinn DH; Kim SE; Kim BK; Kim JH; Choi MS
J Viral Hepat; 2019 Dec; 26(12):1465-1472. PubMed ID: 31332935
[TBL] [Abstract][Full Text] [Related]
16. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term.
Haga H; Saito T; Okumoto K; Tomita K; Katsumi T; Mizuno K; Nishina T; Watanabe H; Ueno Y
J Viral Hepat; 2019 Jul; 26(7):866-872. PubMed ID: 30924226
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between alanine aminotransaminase level and hepatocellular carcinoma in antiviral therapy of chronic viral hepatitis].
Zhang L; Hu P
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):838-841. PubMed ID: 31941238
[TBL] [Abstract][Full Text] [Related]
18. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
19. Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma.
Sherman M; Llovet JM
J Natl Cancer Inst; 2011 Nov; 103(22):1642-3. PubMed ID: 22021668
[No Abstract] [Full Text] [Related]
20. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
